Citations

Clear

5 citation(s) found for "Williams, Lesley".

A scoping review of enteral and parenteral nutrition use in adolescents and adults with avoidant/restrictive food intake disorder
Williams, Lesley, Bering, Jamie, Plotkin, Millie , Napolitano, Marilyn , Staller, Kyle , Bering, Jamie , Burton-Murray, Helen

Mayo Clinic

Eating Disorders | September 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-32

10.1080/10640266.2026.2731474 | PMID 42733129 Get It

Screening and Monitoring for Eating Disorders in Youth Presenting for Obesity Treatment
Tanner, Anna B. , Williams, Alison , Williams, Lesley, Goldschmidt, Andrea B.

Mayo Clinic

Pediatrics Open Science | January 22, 2025 | Volume: 1 | Issue: 1 | Pages: 1-4

10.1542/pedsos.2024-000333 | PMID 40365602 Get It

Creating an appetite awareness and lifestyle modification intervention for Black women at risk for binge eating disorder: A pilot open trial
Goode, Rachel W. , Bardone‐Cone, Anna M. , Wilhoit-Reeves, Stephanie B., Williams, Lesley, Malian, Hannah M., Coan, Danielle, Noem, Taylor, Tate, Deborah F. , Tate, Deborah F

Mayo Clinic

Clinical Obesity | July 28, 2023 | Volume: 13 | Issue: 6 | Pages: No page available

10.1111/cob.12613 | PMID 37501401 Get It

SummaryDespite the availability of evidence‐based interventions to improve binge eating, Black women have some of the lowest rates of access to care for eating disorders. Innovation is needed to offer accessible and culturally relevant treatment options. To this end, using an open trial design, we investigated the feasibility and acceptability of a group‐based, appetite awareness training (AAT) + lifestyle modification (LM) programme in Black women at risk for BED in a primary care setting. Participants (n = 20) were Black women recruited from a family medicine centre affiliated with a local public university, and who reported at least two binge eating episodes in the last 28 days. Participants completed a 16‐session AAT + LM programme over 4 months. Key outcomes were objective binge eating (assessed by the EDE and the EDE‐Q), body dissatisfaction, and weight change, all assessed at baseline, four (post‐treatment) and 6 months (2‐month follow‐up). Ninety‐five percent of participants completed assessments at post‐treatment and attended nearly 60% of intervention sessions. Among completers (n = 19), body dissatisfaction and objective binge eating decreased from baseline to post‐treatment and this decrease was maintained at the 2‐month follow‐up. In exit interviews, participants reported programme satisfaction. Providing training in appetite awareness combined with lifestyle modification principles may be useful in the treatment of body dissatisfaction and binge eating among Black women.
Integrating Health at Every Size principles into adolescent care
Raffoul, Amanda , Williams, Lesley

Mayo Clinic

Current Opinion in Pediatrics | May 18, 2021 | Volume: 33 | Issue: 4 | Pages: 361-367

10.1097/mop.0000000000001023 | PMID 34001715 Get It

Purpose of review Weight trends continue to increase in adolescents, but current weight-focused interventions have not demonstrated any lasting impact on overall health. Among adolescents, experiencing weight bias increases risks of harmful weight-related behaviors and decreases engagement in health-promoting behaviors, thus leading to worsened health outcomes. The Health at Every Size (HAES) approach may be an avenue to promote health holistically among adolescents without eliciting harmful weight-related behavior and improving provider-patient rapport. The purpose of this review is to summarize the literature on integrating HAES principles into healthcare and to generate recommendations for healthcare providers. Recent findings Research among adults shows that HAES-informed care can improve some physical health measures and generates improvements in behavioral and psychological outcomes, as well as promotion of social justice and equity. HAES-informed recommendations for adolescent care de-emphasize weight loss and focus on removing barriers to engaging in health-promoting behaviors at the point of assessment, in the diagnosis and management of medical complications, and in treatment. Summary HAES principles can be an invaluable tool for providers who aim to improve overall health whilst avoiding a focus on weight among their clients.
A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).
Greengard, Emily , Williams, Robin Lesley, Liu, Xiaowei , Militano, Olga, Fisher, Terrence L. , Voss, Stephan D. , Fox, Elizabeth , Weigel, Brenda J. , Evans, Elizabeth E. , Minard, Charles G. , Reid, Joel M. , Berg, Stacey L.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: e21519-e21519

10.1200/jco.2019.37.15_suppl.e21519 Get It

e21519 Background: Semaphorins regulate tumor progression, immune responses, and angiogenesis. SEMA4D was identified as a candidate proto-oncogene by a Sleeping Beauty forward genetic screen that induced osteosarcoma in mice. SEMA4D is expressed on tumors, including osteosarcoma, and in the tumor microenvironment. VX15/2503, a humanized IgG4 monoclonal antibody, binds SEMA4D, blocks receptor interaction and enhances the anti-tumor immune response in preclinical studies. This trial aimed to determine the tolerability and recommended dose of VX15/2503 in patients with relapsed/refractory solid tumors and activity in patients with osteosarcoma. Methods: Part A enrolled patients age≤ 21y with refractory solid tumors to assess the tolerability of VX15/2503 (20 mg/kg) IV every 14 days x 2 doses/cycle. The recommended dose was one that was tolerated and achieved sustained target saturation. Up to 6 additional children were enrolled to assess pharmacokinetics (PK). In part B, a two-stage design was used to assess the activity of VX15/2503 in patients with measurable, relapsed /refractory osteosarcoma. In part B1 patients > 21-30y accrued concurrently with part A; Part B2 (patients £ 21y) was initiated after the pediatric recommended dose was determined. Correlative studies including target saturation by VX15/2503 were required. Results: 18 eligible patients enrolled, 16 evaluable for toxicity. In part A (n = 12) the median (range) age was 12.5 (1-20) y. Diagnoses included osteosarcoma (8), neuroblastoma (2), other (2). No dose limiting toxicities (DLTs) were observed. In Part B1, (n = 6) median (range) age was 22.5 (22-30) y; one patient had cycle 1 DLTs (grade 3 acute kidney injury, creatinine increase, arthralgia and myalgia); a second patient had a later cycle DLT (grade 4 pericardial effusion). Given only 1/18 had a cycle 1 DLT, this did not impact dose selection. T-cell saturation by VX15/2503 was adequate and sustained in all patients. Conclusions: VX15/2503 was well tolerated at 20 mg/kg IV every 2 weeks and is the recommended dose in children, adolescents and young adults. The activity in osteosarcoma is under evaluation. Future trials combining VX15/2503 with novel agents are in development. Clinical trial information: NCT03320330.